CMV Management Post Lung Transplant

Risk Assessment and Prophylaxis Strategy

The National Comprehensive Cancer Network recommends a strategy of CMV surveillance testing by PCR followed by preemptive therapy for positive results, with consideration of letermovir prophylaxis through day 100 post-transplant for high-risk patients 1
CMV infections are common in lung transplant recipients, with 50-60% of CMV-seropositive recipients experiencing reactivation and 10-30% developing CMV disease despite prophylaxis 2
Risk factors for CMV disease include donor CMV-seropositive/recipient-negative (D+/R-) status, which is the highest risk 2
The use of T-cell depleting agents or treatment for rejection is a risk factor for CMV disease 1

The National Comprehensive Cancer Network recommends primary prophylaxis options, including valganciclovir 900 mg once daily for at least 3-6 months post-transplant 1
Letermovir may be considered for CMV-seropositive recipients through day 100 post-transplant, but it lacks HSV/VZV coverage, so continue HSV/VZV prophylaxis 1

Weekly quantitative CMV viral load monitoring by PCR is recommended for at least 3-6 months post-transplant 1, 3
Surveillance should continue during periods of augmented immunosuppression, such as treatment for rejection 1

Upon detection of CMV viremia, first-line treatment is valganciclovir 900 mg orally twice daily, adjusted for renal function 1, 3
Alternative treatment is intravenous ganciclovir 5 mg/kg twice daily if concerns about absorption or severe disease 1
For non-severe CMV disease, oral valganciclovir 900 mg twice daily is recommended, adjusted for renal function 4
For severe or tissue-invasive CMV disease, intravenous ganciclovir 5 mg/kg twice daily is recommended 4

Weekly monitoring of CMV viral load is recommended during treatment 4
Medication side effects should be monitored, including neutropenia and thrombocytopenia for ganciclovir/valganciclovir, and nephrotoxicity and electrolyte abnormalities for foscarnet 1

Acyclovir and valacyclovir are not recommended for CMV prophylaxis or treatment due to their weak activity against CMV 1

The National Comprehensive Cancer Network recommends continuing treatment with valganciclovir for at least 2 weeks and until CMV is no longer detectable by PCR, with weekly monitoring of CMV viral load during treatment to assess response 5
The National Comprehensive Cancer Network suggests considering foscarnet for ganciclovir-resistant CMV or when ganciclovir is not tolerated due to myelosuppression, and maribavir for refractory cases with infectious disease consultation 5
Weekly quantitative CMV viral load monitoring by PCR during treatment is recommended, with continued surveillance for at least 3-6 months post-transplant and during periods of augmented immunosuppression 5
Monitoring for medication side effects, including nephrotoxicity and electrolyte abnormalities with foscarnet, is necessary 5

The American Society of Transplantation defines CMV disease differently from asymptomatic CMV infection, with presence of CMV in BAL without symptoms representing asymptomatic infection but still warranting treatment 6

A weekly surveillance with preemptive therapy approach is effective in preventing progression to symptomatic disease 5

The NCCN guidelines state that maribavir exhibits no nephrotoxicity, providing a distinct renal safety advantage over foscarnet and cidofovir. 7
In a pivotal phase III randomized trial, acute kidney injury occurred in 8.5 % of patients receiving maribavir versus 21.3 % of those receiving foscarnet, indicating significantly lower renal injury with maribavir. 7

Maribavir is associated with minimal myelosuppression; neutropenia was observed in only 9.4 % of patients, compared with 33.9 % in patients treated with valganciclovir/ganciclovir. 7

In refractory CMV infection, maribavir achieved a 56 % viral clearance rate while avoiding the high acute‑kidney‑injury rate (21.3 %) seen with foscarnet. 7

Cidofovir is recognized for significant nephrotoxicity that limits its use in transplant recipients. 8
The same nephrotoxicity concern for cidofovir is corroborated by an additional study. 9